1,027 material Form 8-K filings that 835 companies we cover made with the SEC in February 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On February 19, 2025, ADMA Biologics' board approved 2025 base salaries, 2024 cash bonuses and new equity awards for CEO Adam S. Grossman, COO Kaitlin Kestenberg and CFO Brad Tade. The board also approved a higher annual equity grant policy and higher committee retainers for non-employee directors, effective January 1, 2025.
Grossman's 2025 base salary is $925,000 and his 2024 non-equity incentive compensation is $1,020,000.
Grants made February 19, 2025 at $16.07 per share, the Nasdaq closing price on the grant date, include 252,022 RSUs and 376,744 options for Grossman.
Non-employee directors will receive $350,000 of annual long-term incentive value, split 50% RSUs and 50% options.
Audit Committee chair retainer rises to $25,000 from the filing's stated levels, effective January 1, 2025.
On February 18, 2025, L3Harris entered a new $2.5 billion, five-year senior unsecured revolving credit facility with JPMorgan Chase Bank as administrative agent, replacing its prior $2 billion facility from July 29, 2022, which the company says incurred no early termination penalties. The company also set up a new $500 million, 364-day revolving facility to replace a $1.5 billion facility that matured on January 24, 2025. The filing describes the terms of these refinancings and does not state any amounts drawn under them, and the excerpt ends partway through Item 2.03.
New $2.5 billion revolver matures February 18, 2030, with a possible one-year extension under certain circumstances.
Prior $2 billion facility dated July 29, 2022 was terminated; the filing says no early termination penalties were incurred.
New $500 million 364-day facility commitments run through February 17, 2026, replacing a $1.5 billion facility that matured January 24, 2025.
Initial interest margin on the $2.5 billion facility is 1.125% over term SOFR, adjustable based on L3Harris senior debt ratings.
National Presto reported 2024 net sales of $388.2 million, up 13.9%, and net earnings of $41.5 million, or $5.82 per share, up 20% from 2023. Growth was led by the Defense segment, which shipped from its backlog. The company said there will be no extra dividend in 2025, citing the cash needed to build inventory for a Defense backlog that now exceeds $1 billion.
Net sales rose $47.3 million, or 13.9%, to $388.2 million from $340.9 million in 2023.
Net earnings rose to $41.5 million, or $5.82 per share, from $34.6 million, or $4.86 per share, in 2023.
Defense segment sales rose $42.3 million, or 17.5%; the Safety segment reported a loss.
The Board declared a regular 2025 dividend of $1.00 per share, and no extra dividend will be paid in 2025.
Eastman Chemical issued $250 million of 5.000% notes due August 1, 2029, in a public offering, adding to $500 million of the same notes issued in August 2024. The company expects net proceeds of about $246.2 million for general corporate purposes, including working capital, capital expenditures and debt repayment.
Notes: $250 million principal, 5.000% coupon, maturing August 1, 2029, issued February 21, 2025
Expected net proceeds of approximately $246.2 million after underwriting discounts and offering expenses
Underwriting Agreement dated February 18, 2025, with BofA Securities and J.P. Morgan Securities as representatives
Notes form a single series with the $500 million of 5.000% notes issued August 1, 2024
On February 19, 2025, Molina Healthcare entered a third amendment to its credit agreement with Truist Bank as administrative agent, which amends and restates the prior agreement dated June 8, 2020. The amendment adds a $500 million delayed draw commitment that can be drawn for general corporate purposes if the company meets pro forma financial covenants. For shareholders, this adds committed borrowing capacity, though the filing does not say whether any amount has been drawn.
Third amendment dated February 19, 2025, with Truist Bank as administrative agent; prior agreement dated June 8, 2020
$500 million delayed draw commitment, available until June 19, 2025, with a maturity date of February 19, 2027
Applicable margin of 0.125% for base rate loans and 1.125% for SOFR-based loans; ticking fee of 0.25% per annum on the unused commitment
HCA Inc., a wholly owned subsidiary of HCA Healthcare, completed a public offering of $5.25 billion in senior notes on February 21, 2025, across six tranches maturing between 2028 and 2055. The notes are guaranteed on a senior unsecured basis by HCA Healthcare, and the filing adds $5.25 billion of direct financial obligations to the company's debt.
Six tranches total $5.25 billion: $700 million 5.000% notes due 2028, $300 million floating rate notes due 2028, $750 million 5.250% notes due 2030, $750 million 5.500% notes due 2032, $1.5 billion 5.750% notes due 2035 and $1.25 billion 6.
Interest on the fixed-rate notes is payable semi-annually on March 1 and September 1, starting September 1, 2025
The notes were sold under a shelf registration filed May 1, 2023, with underwriters including BofA Securities, Barclays and J.P. Morgan, under an underwriting agreement dated February 18, 2025
HEI reported a 2024 net loss of $1,426 million, or $11.23 per share, compared with net income of $199 million, or $1.81 per share, in 2023. The result reflects a $1,875 million utility charge for estimated wildfire liabilities from tort-related claims as of December 31, 2024; excluding special items, core income from continuing operations was $124 million, or $0.98 per share, versus $152 million, or $1.38 per share, a year earlier. The filing also cites a February 10, 2025 Hawaii Supreme Court decision that the company says clarifies the path toward resolving the Maui wildfire tort litigation, and the utility dividend to HEI remains suspended.
Full-year 2024 net loss of $1,426 million ($11.23 per share) vs. net income of $199 million ($1.81 per share) in 2023
Core income from continuing operations of $124 million ($0.98 per share) vs. $152 million ($1.38 per share) in 2023
Fourth quarter 2024 net loss of $68 million ($0.40 per share) vs. net income of $49 million ($0.44 per share) in Q4 2023
Utility recorded a $1,875 million loss from accrual of estimated wildfire liabilities as of December 31, 2024, net of insurance recoveries
Gaming and Leisure Properties reported fourth quarter 2024 total revenue of $389.6 million, up from $369.0 million a year earlier, and net income of $223.6 million, compared with $217.3 million. It also issued 2025 AFFO guidance of $1.105 billion to $1.121 billion, or $3.83 to $3.88 per diluted share and OP unit, against $3.77 reported for 2024, which gives shareholders a forward range to compare with the 2024 results.
Q4 2024 total revenue was $389.6 million, versus $369.0 million in Q4 2023; net income was $223.6 million, versus $217.3 million.
Q4 2024 diluted net income per share was $0.79, versus $0.78; AFFO was $269.7 million, versus $256.6 million.
2025 AFFO guidance is $1.105 billion to $1.121 billion, or $3.83 to $3.88 per diluted share and OP unit; full-year 2024 AFFO per share was $3.77.
Board declared a first quarter 2025 dividend of $0.76 per share, payable March 28, 2025, to holders of record on March 14, 2025.
Exelon sold $1.0 billion of senior notes on February 21, 2025, split into $500 million of 5.125% notes due 2031 and $500 million of 5.875% notes due 2055. Part of the proceeds, with available cash, will repay $464 million of commercial paper borrowings that carried a weighted average rate of 4.537% as of February 11, 2025, and the rest will fund general corporate purposes. The filing describes a financing transaction that adds long-term debt rather than a change to operations or earnings.
Notes: $500 million of 5.125% due March 15, 2031 and $500 million of 5.875% due March 15, 2055
Interest paid semi-annually on March 15 and September 15, starting September 15, 2025
$464 million of proceeds plus cash on hand to repay commercial paper at about 4.537% weighted average rate
Sunstone Hotel Investors reported sharply lower fourth-quarter and full-year 2024 profit compared with 2023, when results included a hotel sale gain. Full-year 2024 net income of $43.3 million beat the midpoint of the company's November 2024 guidance, and the company guided to 2025 net income of $46 million to $71 million. The filing also says the CEO and CFO raised their cash bonus target percentages in a February 18, 2025 amended employment agreement.
Q4 2024 net income was $0.8 million, versus $127.0 million in Q4 2023; Q4 loss per diluted share was $0.02, versus earnings of $0.60.
Full-year 2024 net income was $43.3 million, versus $206.7 million in 2023; full-year adjusted EBITDA fell 12.8% to $229.7 million.
Full-year 2024 net income of $43 million exceeded the $31 million to $41 million guidance range given on November 12, 2024.
On February 18, 2025, CEO Bryan A. Giglia's target cash bonus rose from 135% to 150% and CFO Aaron R. Reyes's from 100% to 115%.
Balchem reported fourth quarter 2024 results on February 21, 2025, with net sales of $240.0 million, up 4.9% from the prior year quarter, and GAAP net earnings of $33.6 million, up 26.0%. For the full year, net sales were $953.7 million and GAAP earnings per share were $3.93, compared with $3.35 in 2023. The filing gives no new financial guidance.
Q4 2024 net sales $240.0 million, up $11.3 million or 4.9%
Q4 GAAP diluted EPS $1.03 vs. $0.82; adjusted EPS $1.13 vs. $0.95
Full-year 2024 GAAP net earnings $128.5 million, up 18.4%; adjusted EBITDA $250.3 million, up 8.4%
Full-year free cash flow $147.2 million; company paid down $119.6 million of debt
Protagonist Therapeutics reported fourth-quarter and full-year 2024 results. Net income was $131.7 million, or $2.11 per basic share, in the fourth quarter, up from $27.3 million a year earlier, and $275.2 million for 2024, compared with a net loss of $79.0 million in 2023. The company said its cash position, including a $165.0 million milestone payment received in January 2025, should fund operations through at least the end of 2028.
Q4 2024 license and collaboration revenue was $170.6 million, versus $60.0 million in Q4 2023.
Full-year 2024 license and collaboration revenue was $434.4 million, versus $60.0 million in 2023, mainly from the Takeda agreement and the JNJ milestones.
Cash, cash equivalents and marketable securities were $559.2 million as of December 31, 2024, compared with $341.6 million a year earlier.
Topline results from the Phase 3 VERIFY rusfertide trial and the Phase 2b ANTHEM icotrokinra trial are expected in March 2025.
Brady Corporation reported fiscal 2025 second-quarter sales of $356.7 million, up 10.6% from a year earlier, with acquisitions adding 10.2 points. GAAP diluted EPS fell 7.8% to $0.83, while adjusted diluted EPS rose 7.5% to $1.00, and the company raised the low end of its full-year adjusted EPS guidance. The company also lowered its GAAP EPS guidance to $3.99 to $4.24 to reflect facility closure and reorganization costs.
Q2 net sales of $356.7 million, up 10.6%; organic sales grew 2.6%
GAAP diluted EPS of $0.83 versus $0.90; adjusted diluted EPS of $1.00 versus $0.93
Full-year adjusted EPS guidance low end raised to $4.45 from $4.40; range now $4.45 to $4.70
GAAP EPS guidance updated to $3.99 to $4.24 from $4.02 to $4.32 for facility closure costs
Atmus Filtration Technologies reported fourth-quarter and full-year 2024 results, with full-year net income of $186 million and diluted earnings per share of $2.22, compared with $171 million and $2.05 in 2023. The company also issued 2025 guidance of $1,670 million to $1,735 million in revenue and adjusted earnings per share of $2.35 to $2.60, and said $130 million remained under its $150 million share repurchase authorization as of December 31, 2024.
Full-year 2024 net sales were $1,670 million, up 2.5% from the prior year; fourth-quarter net sales were $407 million, up 1.8%.
Full-year diluted EPS was $2.22 versus $2.05 in 2023; adjusted EPS was $2.50 versus $2.31.
Fourth-quarter operating cash flow was $20 million, compared with $42 million in the fourth quarter of 2023.
2025 guidance: revenue of $1,670 million to $1,735 million, adjusted EBITDA margin of 19.0% to 20.0%, and adjusted EPS of $2.35 to $2.60.
Alcoa Chairman Steven W. Williams notified the company on February 20, 2025, that he will not seek re-election to the Board at the 2025 Annual Meeting of Stockholders. He will remain chairman until his term ends at that meeting, and the filing says the decision is not due to any disagreement with the Board or the company. Board size will shrink to eleven directors after the meeting.
Steven W. Williams will not stand for re-election at the 2025 Annual Meeting of Stockholders
Williams has served as a director since Alcoa's 2016 launch as a public company and as Chairman since 2021
Board size will be reduced to eleven directors immediately upon the end of his term
The filing states the departure is not due to any disagreement with the Board or the company
3M disclosed that Peter Gibbons, Group President of Enterprise Supply Chain, intends to retire, effective April 2, 2025. The filing does not name a successor or describe any compensation arrangements tied to the departure.
Peter Gibbons, Group President, Enterprise Supply Chain, announced his intention to retire.
Retirement is effective April 2, 2025.
The filing was signed by Kevin H. Rhodes, Executive Vice President, Chief Legal Affairs Officer, and Secretary, on February 21, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.